100 related articles for article (PubMed ID: 25568936)
1. Analysis of individual protein regions provides novel insights on cancer pharmacogenomics.
Porta Pardo E; Godzik A
PLoS Comput Biol; 2015 Jan; 11(1):e1004024. PubMed ID: 25568936
[TBL] [Abstract][Full Text] [Related]
2. Improved anticancer drug response prediction in cell lines using matrix factorization with similarity regularization.
Wang L; Li X; Zhang L; Gao Q
BMC Cancer; 2017 Aug; 17(1):513. PubMed ID: 28768489
[TBL] [Abstract][Full Text] [Related]
3. Association analysis of the perturbation of interactions in biological pathways and anticancer drug activity.
Lee J; Lee D
Biochem Biophys Res Commun; 2016 Jan; 470(1):137-143. PubMed ID: 26772881
[TBL] [Abstract][Full Text] [Related]
4. Cancer3D: understanding cancer mutations through protein structures.
Porta-Pardo E; Hrabe T; Godzik A
Nucleic Acids Res; 2015 Jan; 43(Database issue):D968-73. PubMed ID: 25392415
[TBL] [Abstract][Full Text] [Related]
5. Optimal drug prediction from personal genomics profiles.
Sheng J; Li F; Wong ST
IEEE J Biomed Health Inform; 2015 Jul; 19(4):1264-70. PubMed ID: 25781964
[TBL] [Abstract][Full Text] [Related]
6. Comparison and validation of genomic predictors for anticancer drug sensitivity.
Papillon-Cavanagh S; De Jay N; Hachem N; Olsen C; Bontempi G; Aerts HJ; Quackenbush J; Haibe-Kains B
J Am Med Inform Assoc; 2013; 20(4):597-602. PubMed ID: 23355484
[TBL] [Abstract][Full Text] [Related]
7. CancerResource--updated database of cancer-relevant proteins, mutations and interacting drugs.
Gohlke BO; Nickel J; Otto R; Dunkel M; Preissner R
Nucleic Acids Res; 2016 Jan; 44(D1):D932-7. PubMed ID: 26590406
[TBL] [Abstract][Full Text] [Related]
8. Cancer3D 2.0: interactive analysis of 3D patterns of cancer mutations in cancer subsets.
Sedova M; Iyer M; Li Z; Jaroszewski L; Post KW; Hrabe T; Porta-Pardo E; Godzik A
Nucleic Acids Res; 2019 Jan; 47(D1):D895-D899. PubMed ID: 30407596
[TBL] [Abstract][Full Text] [Related]
9. New insight for pharmacogenomics studies from the transcriptional analysis of two large-scale cancer cell line panels.
Sadacca B; Hamy AS; Laurent C; Gestraud P; Bonsang-Kitzis H; Pinheiro A; Abecassis J; Neuvial P; Reyal F
Sci Rep; 2017 Nov; 7(1):15126. PubMed ID: 29123141
[TBL] [Abstract][Full Text] [Related]
10. Pharmacogenetics and pharmacogenomics in oncology therapeutic antibody development.
Yan L; Beckman RA
Biotechniques; 2005 Oct; 39(4):565-8. PubMed ID: 16235569
[TBL] [Abstract][Full Text] [Related]
11. Computational Analyses Connect Small-Molecule Sensitivity to Cellular Features Using Large Panels of Cancer Cell Lines.
Rees MG; Seashore-Ludlow B; Clemons PA
Methods Mol Biol; 2019; 1888():233-254. PubMed ID: 30519951
[TBL] [Abstract][Full Text] [Related]
12. Cancerouspdomains: comprehensive analysis of cancer type-specific recurrent somatic mutations in proteins and domains.
Hashemi S; Nowzari Dalini A; Jalali A; Banaei-Moghaddam AM; Razaghi-Moghadam Z
BMC Bioinformatics; 2017 Aug; 18(1):370. PubMed ID: 28814324
[TBL] [Abstract][Full Text] [Related]
13. Pharmacogenetics of anticancer drug sensitivity in non-small cell lung cancer.
Danesi R; de Braud F; Fogli S; de Pas TM; Di Paolo A; Curigliano G; Del Tacca M
Pharmacol Rev; 2003 Mar; 55(1):57-103. PubMed ID: 12615954
[TBL] [Abstract][Full Text] [Related]
14. Pharmacogenomics in the treatment of lung cancer: an update.
Morales-Espinosa D; García-Román S; Karachaliou N; Rosell R
Pharmacogenomics; 2015; 16(15):1751-60. PubMed ID: 26427522
[TBL] [Abstract][Full Text] [Related]
15. Pharmacogenetics and pharmacogenomics in oncology therapeutic antibody development.
Yan L; Beckman R
Biotechniques; 2005 Oct; 39(10 Suppl):S565-8. PubMed ID: 18957038
[TBL] [Abstract][Full Text] [Related]
16. DISIS: prediction of drug response through an iterative sure independence screening.
Fang Y; Qin Y; Zhang N; Wang J; Wang H; Zheng X
PLoS One; 2015; 10(3):e0120408. PubMed ID: 25794193
[TBL] [Abstract][Full Text] [Related]
17. Clinically relevant cancer biomarkers and pharmacogenetic assays.
Patel JN; Mandock K; McLeod HL
J Oncol Pharm Pract; 2014 Feb; 20(1):65-72. PubMed ID: 23353710
[TBL] [Abstract][Full Text] [Related]
18. Importance of molecular computer modeling in anticancer drug development.
Geromichalos GD
J BUON; 2007 Sep; 12 Suppl 1():S101-18. PubMed ID: 17935268
[TBL] [Abstract][Full Text] [Related]
19. Pharmacogenomics of intrinsic and acquired pharmacoresistance in colorectal cancer: Toward targeted personalized therapy.
De Mattia E; Cecchin E; Toffoli G
Drug Resist Updat; 2015 May; 20():39-70. PubMed ID: 26027741
[TBL] [Abstract][Full Text] [Related]
20. Interactome-wide prediction of short, disordered protein interaction motifs in humans.
Edwards RJ; Davey NE; O'Brien K; Shields DC
Mol Biosyst; 2012 Jan; 8(1):282-95. PubMed ID: 21879107
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
